Quince Therapeutics, Inc. — Form 8-K
Filed September 4, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
Quince Therapeutics filed an 8-K on September 4, 2026 reporting Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The filing indicates the company has received notice of failure to meet continued listing requirements, though specific listing standard violations and remediation timeline are not detailed in the header materials provided.
Why this rating
Delisting is existential threat to public company; eliminates trading liquidity, investor access, and typically precedes bankruptcy or restructuring for small-cap biotech.
Extracted items
Tradability signal
NO TRADE
No trade: negative news, but this cell's evidence is too weak. Similar past filings (3 in this cell) moved -7.35% in the called direction over 4 hrs; shrunk for sample size that's a -0.79% edge.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
at our read · unknown $30.55 | +10 min · unknown $30.55 ▲ 0.00% | +30 min · unknown $30.55 ▲ 0.00% | +1 hr · unknown $30.53 ▼ 0.07% | +4 hrs pending |
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.